Enzymotec Ltd. (NASDAQ:ENZY) shares were down 4.8% during trading on Thursday . The company traded as low as $8.27 and last traded at $8.55, with a volume of 52,212 shares changing hands. The stock had previously closed at $8.98.

A number of research analysts have recently commented on ENZY shares. Zacks Investment Research upgraded Enzymotec from a “hold” rating to a “buy” rating and set a $9.00 price objective on the stock in a report on Tuesday, May 24th. Jefferies Group reiterated a “hold” rating on shares of Enzymotec in a report on Wednesday, June 15th. Finally, Canaccord Genuity reiterated a “hold” rating on shares of Enzymotec in a report on Sunday, April 17th.

The stock has a market cap of $202.00 million and a PE ratio of 33.00. The stock has a 50-day moving average price of $8.35 and a 200-day moving average price of $8.50.

Enzymotec (NASDAQ:ENZY) last issued its quarterly earnings data on Thursday, May 19th. The company reported $0.09 EPS for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.04. During the same quarter in the prior year, the firm earned $0.09 EPS. The company had revenue of $14 million for the quarter, compared to analyst estimates of $13.85 million. The company’s revenue for the quarter was up 23.9% compared to the same quarter last year. Analysts expect that Enzymotec Ltd. will post $0.29 earnings per share for the current fiscal year.

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enable it to develop differentiated solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.